Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1OTHER_GOV 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 21Stomach Neoplasms 14Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Rectal Neoplasms 7Triple Negative Breast Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Small Cell Lung Carcinoma 4Lymphoma, Extranodal NK-T-Cell 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Brain Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Vomiting 2Sarcoma 2Recurrence 2Nasopharyngeal Carcinoma 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2HER2-positive Breast Cancer 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Lung 1Radiation Injuries 1Platinum-resistant Recurrent Ovarian Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pain 1Ovarian Neoplasms 1

Interventions

S 1 (combination) 1Docetaxel 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × UNKNOWN × Breast Cancer Recurrent × Clear all
NCT02947061 2016-10-31

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

ChineseAMS

Phase 2 Unknown
300 enrolled
Breast

Breast Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡